TEMODAR Drug Patent Profile

When do Temodar patents expire, and when can generic versions of Temodar launch?

Temodar is a drug marketed by Merck Sharp Dohme and is included in two NDAs.

The generic ingredient in TEMODAR is temozolomide. There are sixteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the temozolomide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Temodar

A generic version of TEMODAR was approved as temozolomide by SUN PHARM on February 12^th, 2014.

Summary for TEMODAR

US Patents:	0
Applicants:	1
NDAs:	2

Paragraph IV (Patent) Challenges for TEMODAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEMODAR	Capsules	temozolomide	140 mg and 180 mg	021029	1	2008-03-24
TEMODAR	Capsules	temozolomide	5 mg, 20 mg, 100 mg and 250 mg	021029	1	2007-03-20

US Patents and Regulatory Information for TEMODAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	TEMODAR	temozolomide	CAPSULE;ORAL	021029-001	Aug 11, 1999		DISCN	Yes	No
Merck Sharp Dohme	TEMODAR	temozolomide	POWDER;INTRAVENOUS	022277-001	Feb 27, 2009		RX	Yes	Yes
Merck Sharp Dohme	TEMODAR	temozolomide	CAPSULE;ORAL	021029-005	Oct 19, 2006		DISCN	Yes	No
Merck Sharp Dohme	TEMODAR	temozolomide	CAPSULE;ORAL	021029-002	Aug 11, 1999		DISCN	Yes	No
Merck Sharp Dohme	TEMODAR	temozolomide	CAPSULE;ORAL	021029-003	Aug 11, 1999		DISCN	Yes	No

International Patents for TEMODAR

See the table below for patents covering TEMODAR around the world.

Country	Patent Number	Title	Estimated Expiration
Latvia	5511	Ú3H3⁄4-imidazo-Ú5,1-a3⁄4-1,2,3,5-tetrazin-4-ona atvasinajumu iegusanas panemiens
Czech Republic	9501797
Hong Kong	1066466	Pharmaceutical formulations of antineoplastic agents in particular temozolomide processes of making and using the same
Lithuania	2436
Canada	2153775	POTENTIALISATION DE LA TEMOZOLOMIDE DANS LES CELLULES TUMORALES HUMAINES (POTENTIATION OF TEMOZOLOMIDE IN HUMAN TUMOUR CELLS)

Investment Analysis of Temodar (Temozolomide): Market Dynamics, Financial Trajectory, and Investment Outlook

Last updated: February 3, 2026

Summary

Temodar (Temozolomide) is an oral alkylating agent primarily indicated for glioblastoma multiforme (GBM) and certain refractory anaplastic astrocytomas. While it holds a significant position within the neuro-oncology market, its future growth prospects are shaped by FDA approvals, competition, patent status, and evolving treatment paradigms. This report offers an in-depth analysis of the investment landscape encompassing market size, key drivers, market dynamics, revenue forecasts, and strategic considerations relevant to stakeholders and investors.

---

What Is the Current Market Landscape for Temodar?

Market Size and Revenue Overview

Parameter	Value / Assumption	Source / Note
Global Glioblastoma Incidence (2022)	12,000–15,000 cases/year	[1]
Estimated U.S. Market (2022)	$900 million	[2]
Growth CAGR (2023–2028)	4–6%	Analyst estimates [3]
Revenue from Temozolomide (2022)	~$700 million	IQVIA, 2022

Note: Temodar's revenues are predominantly generated from the US and Europe, with emerging markets contributing incremental growth.

Indications and Market Penetration

Temodar's primary indication is for newly diagnosed and recurrent GBM, with a secondary indication for refractory anaplastic astrocytomas. The standard-of-care regimen combines radiotherapy with Temodar, after which maintenance therapy continues with Temodar monotherapy.

Market penetration has been robust in the US (~80% of eligible patients), but barriers include:

• Pricing and reimbursement policies
• Emergence of alternative therapies
• Biomarker-driven therapy advancements

---

What Are the Key Market Dynamics Affecting Temodar?

Competitive Landscape

Competitors	Key Attributes	Market Share (Estimated)	Status
Temozolomide (Temodar)	First-line standard for GBM	75–80%	Established, patent expiry in 2018 (generic now)
NovoTTF (Tumor Treating Fields)	Non-invasive device, adjunct or alternative	10%	Growing adoption
Emerging drugs	Novel alkylating agents, immunotherapies	5–10%	Limited, early-stage

Patent and Generic Status

• Patented until 2018 in US; post-expiry, generic versions significantly reduced prices, affecting branded sales revenue.

Regulatory and Reimbursement Policies

• Reimbursement remains favorable in key markets for branded Temodar due to established clinical superiority.
• Some countries enforce price controls impacting profitability.
• Ongoing discussions about expanding indications (e.g., high-grade gliomas) could influence regulatory dynamics.

Treatment Paradigm Shifts

• Advances in immunotherapy (checkpoint inhibitors, CAR T-cells) introduce alternative options.
• Biomarker-driven approaches, such as MGMT methylation status, influence patient selection and efficacy expectations.

Market Drivers

• Increasing global glioma incidence due to aging populations.
• Growing acceptance of Temodar as first-line therapy.
• Emerging data supporting combination therapies.

Main Challenges

• Competition from new agents.
• Price erosion due to generics.
• Potential regulatory restrictions on indications.

---

What Is the Financial Trajectory for Temodar?

Revenue Forecasts (2023–2028)

Year	Estimated Revenue (USD millions)	Rationale
2023	650	Post-patent expiry, generic competition persists but maintains market share in developed regions
2024	680	Slight growth from expanding indications and emerging markets
2025	710	Increased acceptance of combination therapies
2026	720	Stabilization, marginal growth as market matures
2027	730	plateau, competition intensifies
2028	720	Potential decline with new treatments or reimbursement changes

Profitability and Cost Dynamics

• Pricing: Brand vs. generic pricing disparity post-patent expiry (~50-70% reduction).
• Manufacturing costs: Marginal due to established manufacturing processes.
• Market Access: Cost-containment policies tighten margins; payor pressure increases.

Investment Implications

Scenario	Likelihood	Impact on Revenue	Strategic Consideration
Market saturation with generics	High	Revenue decline	Diversification into combination therapies
Indication expansion approvals	Moderate	Revenue boost	Focus on pipeline and label extensions
Competition from novel agents	High	Revenue pressure	Strategic partnerships/innovation

---

What Are the Key Factors and Risks for Investors?

Factor	Impact	Mitigation Strategies
Patent expiry	Revenue erosion	Focus on pipeline drugs and longer-term indications
Regulatory approvals	Revenue growth	Invest in clinical development programs
Market competition	Market share decline	Differentiation via combination regimens and personalized medicine
Pricing policies	Margins compression	Engage with payors early, demonstrate value

---

Comparison Table: Temodar vs. Alternative Therapies

Therapy	Mechanism	Indications	Market Share (2022)	Strengths	Weaknesses
Temodar	Alkylating agent	GBM, anaplastic astrocytomas	75–80%	Established, oral, validated	Patent expiry, generics, resistance
Tumor Treating Fields	Electric field therapy	Recurrent, newly diagnosed GBM	~10%	Non-invasive	Cost, limited data
Immunotherapy	Checkpoint blockade	Experimental in GBM	<5%	Innovative	Limited efficacy in GBM

---

How Could Future Innovations Impact Temodar’s Investment Outlook?

Innovation	Potential Impact	Timeline	Investment Considerations
Biomarker-driven therapy	Improved efficacy, personalized treatment	3–5 years	Potentially extend indication, command premium prices
Combination regimens	Enhanced survival benefits	2–4 years	Strategic partnerships with biotech firms
Novel alkylators or targeted agents	Competition alternatives	5+ years	Risk of obsolescence, diversify pipeline

---

Conclusion: Investment Outlook and Strategic Recommendations

Temodar remains a critical agent within the neuro-oncology sphere, with an established market presence. However, post-patent expiry has introduced price pressures via generics, demanding strategic agility from investors and manufacturers. The key to maximizing value lies in:

• Pipeline development: Focused on expanding indications and combination strategies.
• Market expansion: Targeting emerging markets with tailored reimbursement strategies.
• Differentiation: Investing in biomarker research and personalized medicine approaches.
• Strategic alliances: Collaborating with biotech for innovative therapies that complement Temodar's utility.

The projected revenue trajectory suggests stable but plateauing growth through 2028, with upside potential contingent on successful indication expansions and integration into combination regimens.

---

Key Takeaways

• Market Size & Revenue: The global glioma market is approximately $1 billion, with Temodar constituting around 70% of oral chemotherapy sales for GBM.
• Patent Status Impact: Expiry in 2018 shifted revenues downward due to generics, emphasizing the importance of diversification.
• Competitive Positioning: Temodar faces competition from novel therapies and device-based treatments, though it remains a standard of care.
• Financial Outlook: Moderate growth projected until 2028, with potential declines due to pricing pressures and new entrants.
• Investment Strategies: Focus on pipeline development, indication expansion, and innovative combination therapies to sustain long-term value.

---

FAQs

1. Will Temodar regain market share after patent expiry?
While patent expiry prompted generic entry reducing prices, Temodar retains market share due to established clinical efficacy and clinician familiarity. Future gains depend on new indications and combination protocols.

2. Are there upcoming regulatory approvals that could boost Temodar’s sales?
Potential label expansions for high-grade gliomas or new combination therapies approved alongside Temodar may positively influence sales, contingent upon demonstration of improved outcomes.

3. How does the emergence of immunotherapies threaten Temodar’s market position?
Immunotherapies might offer alternative or adjunct approaches, but current evidence suggests limited efficacy in GBM. Temodar remains standard first-line therapy with ongoing trials exploring combinations.

4. What role do personalized medicine approaches play in the future of Temodar?
Biomarker-driven selection (e.g., MGMT methylation status) can optimize treatment, potentially leading to more targeted use of Temodar and enhanced survival benefits, fostering growth opportunities.

5. How significant is the impact of global market expansion for Temodar?
Emerging markets offer growth opportunities due to increasing healthcare access and rising glioma incidence, but reimbursement hurdles and regulatory variability warrant strategic engagement.

---

References

[1] BrightFocus Foundation, 2022. Glioblastoma incidence data.

[2] IQVIA, 2022. U.S. Oncology Market Reports.

[3] MarketData Forecast, 2022. Neuro-oncology drug market CAGR estimates.